NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Conagra Brands, Inc. CAG
Class Period: Pursuant to the SPO on or about October 9, 2018 and/or between June 27, 2018 and December 19, 2018
Lead Plaintiff Deadline: April 23, 2019
Join the action: https://www.zlk.com/pslra-1/conagra-brands-inc-loss-form?wire=3
The complaint alleges that defendants failed to disclose material information, including that (i) Conagra inadequately performed proper due diligence in connection with the acquisition of Pinnacle; (ii) the performance of Pinnacle's three leading brands was not deteriorating due to intensified competition, but to self-inflicted subpar innovation and executional missteps; (iii) Pinnacle's business was performing so poorly that it had resorted to pushing promotional deals to retailers in an effort to boost sales; and (iv) as a result of the foregoing, Defendant's public statements were materially false and/or misleading and/or lacked a reasonable basis when made.
To learn more about the Conagra Brands, Inc. class action contact jlevi@levikorsinsky.com.
Healthcare Services Group, Inc. HCSG
Class Period: April 11, 2017 - March 4, 2019
Lead Plaintiff Deadline: May 21, 2019
Join the action: https://www.zlk.com/pslra-1/healthcare-services-group-inc-loss-form?wire=3
About the lawsuit: Healthcare Services Group, Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (a) Defendant Wahl either knew or was reckless in not knowing that the Company had been accused of strategically rounding quarterly earnings per share, and therefore investors could not rely upon the Company's track record without conducting a thorough investigation into the allegations; (b) Defendants concealed that the SEC had written to the Company in November 2017 to inquire into the Company's earnings per share rounding practices; and (c) the Company concealed that the SEC delivered a subpoena to the Company in March 2018 demanding the Company produce documents in connection with how it calculated earnings per share.
To learn more about the Healthcare Services Group, Inc. class action contact jlevi@levikorsinsky.com.
American Renal Associates Holdings, Inc. ARA
Class Period: August 10, 2016 - March 27, 2019
Lead Plaintiff Deadline: May 28, 2019
Join the action: https://www.zlk.com/pslra-1/american-renal-associates-holdings-inc-loss-form?wire=3
About the lawsuit: During the class period, American Renal Associates Holdings, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission ("SEC") investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times.
To learn more about the American Renal Associates Holdings, Inc. class action contact jlevi@levikorsinsky.com.
Zogenix, Inc. ZGNX
Class Period: February 6, 2019 - April 8, 2019
Lead Plaintiff Deadline: June 11, 2019
Join the action: https://www.zlk.com/pslra-1/zogenix-inc-loss-form?wire=3
About the lawsuit: Zogenix, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Zogenix's NDA for FINTEPLA contained inadequate non-clinical data and an incorrect version of a clinical dataset; (ii) consequently, Zogenix's NDA for FINTEPLA was unlikely to gain FDA approval; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more about the Zogenix, Inc. class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
